Dioverti V, Salto-Alejandre S, Haidar G. Immunocompromised Patients with Protracted COVID-19: a Review of “Long Persisters.” Curr Transplant Rep. 2022;9(4):209–18.

Article  PubMed  PubMed Central  Google Scholar 

Hus, I., Szymczyk, A., Mańko, J., & Drozd-Sokołowska, J. COVID-19 in Adult Patients with Hematological Malignancies—Lessons Learned after Three Years of Pandemic. Biology, 2023;12(4):545. https://doi.org/10.3390/biology12040545.

Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7(10):e737–45.

Article  PubMed  PubMed Central  Google Scholar 

Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136(25):2881–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ljungman P, de la Camara R, Mikulska M, Tridello G, Aguado B, Zahrani MA, et al. COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. Leukemia. 2021;35(10):2885–94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Spanjaart AM, Ljungman P, de La Camara R, Tridello G, Ortiz-Maldonado V, Urbano-Ispizua A, et al. Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group. Leukemia. 2021;35(12):3585–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ferrara F, Zovi A, Trama U, Vitiello A. Nirmatrelvir-remdesivir association for non-hospitalized adults with COVID-19, point of view. Inflammopharmacology. 2022;30(5):1927–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

OntarioHealth. COVID-19 Treatment (accessed October 3rd, 2024): https://www.ontariohealth.ca/providing-health-care/clinical-resources-education/covid-19/treatment?source=PDF&name=Ontario-Health-Recommendations-Outpatient-Use-of-Intravenous-Remdesivir-Veklury-in-Adults.

Morishita M, Suzuki M, Matsunaga A, Ishizhima K, Yamamoto T, Kuroda Y, et al. Prolonged SARS-CoV-2 infection associated with long-term corticosteroid use in a patient with impaired B-cell immunity. J Infect Chemother. 2022;28(7):971–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kajova M, Kekäläinen E, Anttila VJ, Paajanen J. Successful treatment with a short course of remdesivir in a case of prolonged COVID-19 in a lymphoma patient. Infect Dis (Lond). 2022;54(6):455–9.

Article  CAS  PubMed  Google Scholar 

Brown LK, Moran E, Goodman A, Baxendale H, Bermingham W, Buckland M, et al. Treatment of chronic or relapsing COVID-19 in immunodeficiency. J Allergy Clin Immunol. 2022;149(2):557-61.e1.

Article  CAS  PubMed  Google Scholar 

Fujii H, Tsuji T, Sugitani M, Matsumoto Y, Yuba T, Tanaka S, et al. Prolonged persistence of SARS-CoV-2 infection during A+AVD therapy for classical Hodgkin’s lymphoma: A case report. Curr Probl Cancer. 2021;45(6): 100739.

Article  PubMed  PubMed Central  Google Scholar 

Breeden M, Aitken SL, Baang JH, Gravelin M, Kaul DR, Lauring AS, et al. Successful Treatment of Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Patients With Immunodeficiency With Extended Nirmatrelvir/Ritonavir: Case Series. Open Forum Infect Dis. 2023;10(4):ofad189.

Article  PubMed  PubMed Central  Google Scholar 

Ford ES, Simmons W, Karmarkar EN, Yoke LH, Braimah AB, Orozco JJ, et al. Successful Treatment of Prolonged, Severe Coronavirus Disease 2019 Lower Respiratory Tract Disease in a B cell Acute Lymphoblastic Leukemia Patient With an Extended Course of Remdesivir and Nirmatrelvir/Ritonavir. Clin Infect Dis. 2023;76(5):926–9.

Article  PubMed  Google Scholar 

Cohen AK, Jaudon TW, Schurman EM, Kava L, Vogel JM, Haas-Godsil J, et al. Impact of extended-course oral nirmatrelvir/ritonavir in established Long COVID: a case series. Communications Medicine. 2025;4(1):261.

Article  PubMed  PubMed Central  Google Scholar 

Rotundo S, Berardelli L, Gullì S, La Gamba V, Lionello R, Russo A, et al. Early initiation of combined therapy in severely immunocompromised patients with COVID-19: a retrospective cohort study. BMC Infect Dis. 2024;24(1):564.

Article  CAS  PubMed  PubMed Central  Google Scholar 

NIH. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/. Accessed October 3rd, 2024.

Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, et al. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. N Engl J Med. 2022;386(4):305–15.

Article  CAS  PubMed  Google Scholar 

Dormuth CR, Kim JD, Fisher A, Piszczek J, Kuo IF. Nirmatrelvir-Ritonavir and COVID-19 Mortality and Hospitalization Among Patients With Vulnerability to COVID-19 Complications. JAMA Netw Open. 2023;6(10): e2336678.

Article  PubMed  PubMed Central  Google Scholar 

Chen C, Fang J, Chen S, Rajaofera MJN, Li X, Wang B, et al. The efficacy and safety of remdesivir alone and in combination with other drugs for the treatment of COVID-19: a systematic review and meta-analysis. BMC Infect Dis. 2023;23(1):672.

Article  PubMed  PubMed Central  Google Scholar 

Gidari A, Sabbatini S, Schiaroli E, Bastianelli S, Pierucci S, Busti C, Saraca LM, Capogrossi L, Pasticci MB, & Francisci D. Synergistic Activity of Remdesivir–Nirmatrelvir Combination on a SARS-CoV-2 In Vitro Model and a Case Report. Viruses. 2023;15(7):1577. https://doi.org/10.3390/v15071577.

Choi MH, Wan EYF, Wong ICK, Chan EWY, Chu WM, Tam AR, et al. Comparative effectiveness of combination therapy with nirmatrelvir-ritonavir and remdesivir versus monotherapy with remdesivir or nirmatrelvir-ritonavir in patients hospitalised with COVID-19: a target trial emulation study. Lancet Infect Dis. 2024;24(11):1213–24.

Article  CAS  PubMed  Google Scholar 

clinicaltrails.gov identifier NCT05587894; OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial (OPTICOV). Updated 2023-03-28; Registration date: 2022-10-17. Clinical Trial Registry:EMA CTIS #CT-2022-501408-81-01. [Available from: https://clinicaltrials.gov/study/NCT05587894.

Pasquini Z, Toschi A, Casadei B, Pellegrini C, D’Abramo A, Vita S, et al. Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS-CoV-2 infection. Hematol Oncol. 2023;41(5):904–11.

Article  CAS  PubMed  Google Scholar